205 related articles for article (PubMed ID: 25112228)
21. Hyperprolactinemia and prolactinomas.
Mancini T; Casanueva FF; Giustina A
Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
[TBL] [Abstract][Full Text] [Related]
22. Management of prolactinomas during pregnancy.
Witek P; Zieliński G
Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
[TBL] [Abstract][Full Text] [Related]
23. Guidelines for the diagnosis and treatment of hyperprolactinemia.
Biller BM; Luciano A; Crosignani PG; Molitch M; Olive D; Rebar R; Sanfilippo J; Webster J; Zacur H
J Reprod Med; 1999 Dec; 44(12 Suppl):1075-84. PubMed ID: 10649814
[TBL] [Abstract][Full Text] [Related]
24. [Reversible blindness caused by an invasive prolactinoma].
Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C
Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749
[TBL] [Abstract][Full Text] [Related]
25. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Greenman Y; Tordjman K; Stern N
Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
[TBL] [Abstract][Full Text] [Related]
26. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
27. Prolactinoma surgery.
Jan M; Dufour H; Brue T; Jaquet P
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
[TBL] [Abstract][Full Text] [Related]
28. Metabolic effects of prolactin and the role of dopamine agonists: A review.
Kirsch P; Kunadia J; Shah S; Agrawal N
Front Endocrinol (Lausanne); 2022; 13():1002320. PubMed ID: 36246929
[TBL] [Abstract][Full Text] [Related]
29. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
30. Implications of not treating hyperprolactinemia.
Sanfilippo JS
J Reprod Med; 1999 Dec; 44(12 Suppl):1111-5. PubMed ID: 10649820
[TBL] [Abstract][Full Text] [Related]
31. Patient guide to hyperprolactinemia diagnosis and treatment.
Hoffman AR; Melmed S; Schlechte J
J Clin Endocrinol Metab; 2011 Feb; 96(2):35A-6A. PubMed ID: 21296988
[No Abstract] [Full Text] [Related]
32. [Hyperprolactinemia].
Müller OA; von Werder K
Z Arztl Fortbild (Jena); 1991 Feb; 85(3-4):125-30. PubMed ID: 1676201
[No Abstract] [Full Text] [Related]
33. NUTRITIONAL AND METABOLIC ASSESSMENT IN OVERWEIGHT PATIENTS WITH AND WITHOUT HYPERPROLACTINEMIA CAUSED BY PROLACTINOMA.
Breyer Freitas B; Rothen RE; Zeni D; Garcia Soares Leães C; Costa Oliveira M; Michielin Busnello F; Fernanda Semmelmann Pereira-Lima J
Nutr Hosp; 2015 Nov; 32(5):2030-7. PubMed ID: 26545657
[TBL] [Abstract][Full Text] [Related]
34. Clinical presentation of hyperprolactinemia.
Luciano AA
J Reprod Med; 1999 Dec; 44(12 Suppl):1085-90. PubMed ID: 10649815
[TBL] [Abstract][Full Text] [Related]
35. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
[TBL] [Abstract][Full Text] [Related]
36. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
[No Abstract] [Full Text] [Related]
37. A single- center experience of prolactin-producing pituitary adenomas without hyperprolactinemia: Its incidence and clinical management.
Ogawa Y; Tominaga T
Clin Neurol Neurosurg; 2020 Nov; 198():106123. PubMed ID: 32818756
[TBL] [Abstract][Full Text] [Related]
38. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
39. [Abnormal states of prolactin secretion].
Sugino N
Nihon Rinsho; 2006 Apr; 64 Suppl 4():269-74. PubMed ID: 16689320
[No Abstract] [Full Text] [Related]
40. Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
Aboelnaga MM; Eladawy EH; Elshafei MM; Abdullah N; Shaer ME
Endocr Metab Immune Disord Drug Targets; 2019; 19(4):511-518. PubMed ID: 30806330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
